Therapeutic approaches to Chlamydia infections

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 13, 2005, Pages 2281-2290

  Senn, Laurence ^a   Hammerschlag, Margaret R ^b   Greub, Gilbert ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Antibiotics; Antimicrobial agents; Cervicitis; Chlamydia trachomatis; Chlamydophila pneumoniae; Intracellular bacteria; Respiratory tract infection; Trachoma; Urethritis

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ATORVASTATIN; AZITHROMYCIN; CEFOTETAN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; OFLOXACIN; PRAVASTATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; TETRACYCLINE;

ATHEROSCLEROSIS; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONJUNCTIVITIS; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; EYE INFECTION; GASTROINTESTINAL SYMPTOM; HUMAN; INTRACELLULAR SPACE; ISCHEMIC HEART DISEASE; LIFESTYLE; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PELVIC INFLAMMATORY DISEASE; PHOTOSENSITIVITY; PUBLIC HEALTH; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TRACHOMA; URETHRITIS; UROGENITAL TRACT INFECTION; UTERINE CERVICITIS;

ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CONJUNCTIVITIS, INCLUSION; FEMALE UROGENITAL DISEASES; HUMANS; MACROLIDES; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS; TETRACYCLINES; TRACHOMA;

EID: 27744531823     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.13.2281     Document Type: Review

References (75)

1. EVERETT KD, BUSH RM, ANDERSEN AA: Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms. Int. J. Syst. Bacteriol. (1999) 49(Pt 2):415-440.
2. STEPHENS RS, KALMAN S, LAMMEL C et al.: Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science (1998) 282(5389):754-759.
3. KALMAN S, MITCHELL W, MARATHE R et al.: Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat. Genet. (1999) 21(4):385-389.
4. GREUB G, RAOULT D: History of the ADP/ATP-translocase-encoding gene, a parasitism gene transferred from a Chlamydiales ancestor to plants 1 billion years ago. Appl. Environ. Microbiol. (2003) 69(9):5530-5535.
5. MABEY DC, SOLOMON AW, FOSTER A: Trachoma. Lancet (2003) 362(9379):223-229.
6. WEST SK: Trachoma: new assault on an ancient disease. Prog. Retin. Eye Res. (2004) 23(4):381-401.
7. PEIPERT JF: Clinical practice. Genital chlamydial infections. N. Engl. J. Med. (2003) 349(25):2424-2430.
8. BLACK CM: Current methods of laboratory diagnosis of Chlamydia trachomatis infections, Clin. Microbiol. Rev. (1997) 10(1):160-184.
9. LAGA M, MANOKA A, KIVUVU M et al.: Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS (1993) 7(1):95-102.
10. BLASI F: Atypical pathogens and respiratory tract infections. Eur. Respir. J. (2004) 24(1):171-181.
11. CARROLL KC: Laboratory diagnosis of lower respiratory tract infections: controversy and conundrums. J. Clin. Microbiol. (2002) 40(9):3115-3120.
12. MARRIE TJ, POULIN-COSTELLO M, BEECROFT MD, HERMAN-GNJIDIC Z: Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir. Med. (2005) 99(1):60-65.
13. HYMAN CL, ROBLIN PM, GAYDOS CA, QUINN TC, SCHACHTER J, HAMMERSCHLAG MR: Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture. Clin. Infect. Dis. (1995) 20(5):1174-1178.
14. KAUPPINEN MT, SAIKKU P, KUJALA P, HERVA E, SYRJALA H: Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax (1996) 51(2):185-189.
15. KAUPPINEN MT, LAHDE S, SYRJALA H: Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia. Arch. Intern. Med. (1996) 156(16):1851-1856.
16. BELLAND RJ, OUELLETTE SP, GIEFFERS J, BYRNE GI: Chlamydia pneumoniae and atherosclerosis. Cell Microbiol. (2004) 6(2):117-127.
17. GRAYSTON JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J. Infect. Dis. (2000) 181(Suppl. 3):S402-S410.
18. IEVEN MM, HOYMANS VY: Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence. J. Clin. Microbiol. (2005) 43(1):19-24.
19. KALAYOGLU MV, LIBBY P, BYRNE GI: Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA (2002) 288(21):2724-2731.
20. DANESH J, WHINCUP P, LEWINGTON S et al.: Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur. Heart J. (2002) 23(5):371-375.
21. DANESH J, WHINCUP P, WALKER M et al.: Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. Br. Med. J. (2000) 321(7255):208-213.
22. APFALTER P, ASSADIAN O, BLASI F et al.: Reliability of nested PCR for detection of Chlamydia pneumoniae DNA in atheromas: results from a multicenter study applying standardized protocols. J. Clin. Microbiol. (2002) 40(12):4428-4434.
23. BOMAN J, HAMMERSCHLAG MR: Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin. Microbiol. Rev. (2002) 15(1):1-20.
24. GRAYSTON JT: Antibiotic treatment of atherosclerotic cardiovascular disease. Proceedings of the fifth Meeting of the European Society for Chlamydia Research Budapest, Hungary (2004)105-111.
25. O'CONNOR CM, DUNNE MW, PFEFFER MA et al.: Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 290(11):1459-1466.
26. CANNON CP, BRAUNWALD E, MCCABE CH et al.: Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N. Engl. J. Med. (2005) 352(16):1646-1654.
27. GRAYSTON JT, KRONMAL RA, JACKSON LA et al.: Azithromycin for the secondary prevention of coronary events. N. Engl. J. Med. (2005) 352(16):1637-1645.
28. DESSUS-BABUS S, BEBEAR CM, CHARRON A, BEBEAR C, De BARBEYRAC B.: Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob. Agents Chemother. (1998) 42(10):2474-2481.
29. DRESES-WERRINGLOER U, PADUBRIN I, ZEIDLER H, KOHLER L: Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob. Agents Chemother. (2001) 45(11):3001-3008.
30. KUTLIN A, KOHLHOFF S, ROBLIN P, HAMMERSCHLAG MR, RISKA P: Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob. Agents Chemother. (2005) 49(3):903-907.
31. RISKA PF, KUTLIN A, AJIBOYE P, CUA A, ROBLIN PM, HAMMERSCHLAG MR: Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. Antimicrob. Agents Chemother. (2004) 48(9):3586-3590.
32. HAMMERSCHLAG MR: Advances in the management of Chlamydia pneumoniae infections. Expert. Rev. Anti Infect. Ther. (2003) 1(3):493-503.
33. MABEY D, FRASER-HURT N: Antibiotics for trachoma. Cochrane Database Syst. Rev. (2002) (1):CD001860.
34. MABEY D, SOLOMON A: The effect of antibiotic treatment on active trachoma and ocular Chlamydia trachomatis infection. Expert. Rev. Anti. Infect. Ther. (2003) 1(2):209-216.
35. LAU CY, QURESHI AK: Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex. Transm. Dis. (2002) 29(9):497-502.
36. MARTIN DH, MROCZKOWSKI TF, DALU ZA et al.: A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N. Engl. J. Med. (1992) 327(13):921-925.
37. SEGRETI J, KAPELL KS, TRENHOLME GM: In vitro activity of beta-lactam drugs and sulbactam against Chlamydia trachomatis. Diagn. Microbiol. Infect. Dis. (1992) 15(4):371-373.
38. GEISLER WM: Approaches to the management of uncomplicated genital Chlamydia trachomatis infections. Expert. Rev. Anti. Infect. Ther. (2004) 2(5):771-785.
39. SOLOMON AW, PEELING RW, FOSTER A, MABEY DC: Diagnosis and assessment of trachoma. Clin. Microbiol. Rev. (2004) 17(4):982-1011.
40. THYLEFORS B, DAWSON CR, JONES BR, WEST SK, TAYLOR HR: A simple system for the assessment of trachoma and its complications. Bull. World Health Organ. (1987) 65(4):477-483.
41. ADAMU Y, ALEMAYEHU W: A randomized clinical trial of the success rates of bilamellar tarsal rotation and tarsotomy for upper eyelid trachomatous trichiasis. Ethiop. Med. J. (2002) 40(2):107-114.
42. REACHER MH, MUNOZ B, ALGHASSANY A, DAAR AS, ELBUALY M, TAYLOR HR: A controlled trial of surgery for trachomatous trichiasis of the upper lid. Arch. Ophthalmol. (1992) 110(5):667-674.
43. BOG H, YORSTON D, FOSTER A: Results of community-based eyelid surgery for trichiasis due to trachoma. Br. J. Ophthalmol. (1993) 77(2):81-83.
44. SOLOMON AW, HOLLAND MJ, ALEXANDER ND et al.: Mass treatment with single-dose azithromycin for trachoma. N. Engl. J. Med. (2004) 351(19):1962-1971.
45. WEST S, MUNOZ B, LYNCH M et al.: Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet (1995) 345(8943):155-158.
46. HOOK EW 3rd, SMITH K, MULLEN C et al.: Diagnosis of genitourinary Chlamydia trachomatis infections by using the ligase chain reaction on patient-obtained vaginal swabs. J. Clin. Microbiol. (1997) 35(8):2133-2135.
47. HOWELL MR, QUINN TC, GAYDOS CA: Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies. Ann. Intern. Med. (1998) 128(4):277-284.
48. U.S. PREVENTIVE SERVICES TASK FORCE: Screening for chlamydial infection: recommendations and rationale: Am. J. Prev. Med. (2001) 20(3 Suppl.):90-94.
49. EGGER M, LOW N, SMITH GD, LINDBLOM B, HERRMANN B: Screening for chlamydial infections and the risk of ectopic pregnancy in a county in Sweden: ecological analysis. Br. Med. J. (1998) 316(7147):1776-1780.
50. SCHOLES D, STERGACHIS A, HEIDRICH FE, ANDRILLA H, HOLMES KK, STAMM WE: Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N. Engl. J. Med. (1996) 334(21):1362-1366.
51. LAMONTAGNE DS, FENTON KA, RANDALL S, ANDERSON S, CARTER P: Establishing the National Chlamydia Screening Programme in England: results from the first full year of screening. Sex Transm. Infect. (2004) 80(5):335-341.
52. CENTERS FOR DISEASE CONTROL AND PREVENTION: Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention: MMWR Recomm. Rep. (2002) 51(RR-6):1-78.
53. HAMMERSCHLAG MR: Chlamydia trachomatis and Chlamydia pneumoniae infections in children and adolescents. Pediatr. Rev. (2004) 25(2):43-51.
54. MANDELL LA, BARTLETT JG, DOWELL SF, FILE TM Jr, MUSHER DM, WHITNEY C: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. (2003) 37(11):1405-1433.
55. DOWELL SF, PEELING RW, BOMAN J et al.: Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin. Infect. Dis. (2001) 33(4):492-503.
56. HOGAN RJ, MATHEWS SA, MUKHOPADHYAY S, SUMMERSGILL JT, TIMMS P: Chlamydial persistence: beyond the biphasic paradigm. Infect. Immun. (2004) 72(4):1843-1855.
57. ROCKEY DD, LENART J, STEPHENS RS: Genome sequencing and our understanding of chlamydiae. Infect. Immun. (2000) 68(10):5473-5479.
58. LONKS JR, GARAU J, MEDEIROS AA: Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J. Antimicrob. Chemother. (2002) 50(Suppl. S2):87-92.
59. KASTNER U, GUGGENBICHLER JP: Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection (2001) 29(5):251-256.
60. WILLIAMS J, TALLIS G, DALTON C et al.: Community outbreak of psittacosis in a rural Australian town. Lancet (1998) 351(9117):1697-1699.
61. YUNG AP, GRAYSON ML: Psittacosis-a review of 135 cases. Med. J. Aust. (1988) 148(5):228-233.
62. POSPISCHIL A, THOMA R, HILBE M, GREST P, GEBBERS JO: Abortion in woman caused by caprine Chlamydophila abortus (Chlamydia psittaci serovar 1). Swiss. Med. Wkly (2002) 132(5-6):64-66.
63. WALDER G, MEUSBURGER H, HOTZEL H et al.: Chlamydophila abortus pelvic inflammatory disease. Emerg. Infect. Dis. (2003) 9(12):1642-1644.
64. HARTLEY JC, STEVENSON S, ROBINSON AJ et al.: Conjunctivitis due to Chlamydophila felis (Chlamydia psittaci feline pneumonitis agent) acquired from a cat: case report with molecular characterization of isolates from the patient and cat. J. Infect. (2001) 43(1):7-11.
65. MARRIE TJ, PEELING RW, REID T, De CAROLIS E: Chlamydia species as a cause of community-acquired pneumonia in Canada. Eur. Respir. J. (2003) 21(5):779-784.
66. GREUB G, BERGER P, PAPAZIAN L, RAOULT D: Parachlamydiaceae as rare agents of pneumonia. Emerg. Infect. Dis. (2003) 9(6):755-756.
67. GREUB G, BOYADJIEV I, LA SB, RAOULT D, MARTIN C: Serological hint suggesting that Parachlamydiaceae are agents of pneumonia in polytraumatized intensive care patients. Ann. N. Y. Acad. Sci. (2003) 990:311-319.
68. GREUB G, RAOULT D: Parachlamydiaceae: potential emerging pathogens. Emerg. Infect. Dis. (2002) 8(6):625-630.
69. LIEBERMAN D, KAHANE S, LIEBERMAN D, FRIEDMAN MG: Pneumonia with serological evidence of acute infection with the Chlamydia-like microorganism 'Z'. Am. J. Respir. Crit. Care Med. (1997) 156(2 Pt 1):578-582.
70. KAHANE S, GREENBERG D, FRIEDMAN MG, HAIKIN H, DAGAN R: High prevalence of 'Simkania Z,' a novel Chlamydia-like bacterium, in infants with acute bronchiolitis. J. Infect. Dis. (1998) 177(5):1425-1429.
71. MIYASHITA N, MATSUMOTO A, FUKANO H, NIKI Y, MATSUSHIMA T: The 7.5-kb common plasmid is unrelated to the drug susceptibility of Chlamydia trachomatis. J. Infect. Chemother. (2001) 7(2):113-116.
72. NILIUS AM, SHEN LL, HENSEY-RUDLOFF D et al.: In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob. Agents Chemother. (2003) 47(10):3260-3269.
73. SAMRA Z, ROSENBERG S, SOFFER Y, DAN M: In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn. Microbiol. Infect. Dis. (2001) 39(3):177-179.
74. SMELOV V, KRYLOVA T, SMELOVA N, NORMAN L: Azithromycin treatment follow-up: antibacterial susceptibility of Chlamydia trachomatis in patients with chronic prostatitis. Int. J. Antimicrob. Agents (2004) 23(Suppl. 1):S79-S82.
75. SUCHLAND RJ, GEISLER WM, STAMM WE: Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob. Agents Chemother. (2003) 47(2):636-642.